Citigroup
RAPP

Citigroup’s Rapport Therapeutics RAPP Stock Holding History

Citigroup’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Sell
24,373
-54,426
-69% -$2M ﹤0.01% 3434
2026
Q1 		$2.47M Buy
78,799
+22,315
+40% +$628K ﹤0.01% 2531
2025
Q4 		$1.71M Buy
56,484
+54,714
+3,091% +$1.51M ﹤0.01% 2763
2025
Q3 		$52.6K Sell
1,770
-5,283
-75% -$94.2K ﹤0.01% 4478
2025
Q2 		$80.2K Sell
7,053
-8,032
-53% -$85.2K ﹤0.01% 4523
2025
Q1 		$151K Buy
15,085
+5,508
+58% +$71.5K ﹤0.01% 4351
2024
Q4 		$170K Sell
9,577
-3,197
-25% -$70.8K ﹤0.01% 4510
2024
Q3 		$262K Buy
+12,774
New +$274K ﹤0.01% 4158

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Citigroup's RAPP Position: Q2 2026 in Review

Citigroup reduced its Rapport Therapeutics (RAPP) stake by 69% in Q2 2026, selling an estimated $2M and leaving 24,373 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3434.

Citigroup first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.47M in Q1 2026. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Citigroup held 24,373 shares of Rapport Therapeutics worth $1.02M as of Q2 2026.
  • Citigroup sold 54,426 Rapport Therapeutics shares in Q2 2026, an estimated $2M.
  • Rapport Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3434 holding.
  • Citigroup first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Citigroup's Rapport Therapeutics position peaked at $2.47M in Q1 2026.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.